Table 1 Demographic and clinical characteristics of modified intention-to-treat cohort at initial assessment stratified by study arm
Characteristic | Scheduled Ab testing | Usual care | All patients |
|---|---|---|---|
Patients, n (%)* | 653 (53.1) | 577 (46.9) | 1230 (100) |
Age in years, mean ± SD | 45.3 ± 10.6 | 45 · 1 ± 9.8 | 45.2 ± 10.2 |
Caucasians, n (%)† | 551 (84.4) | 495 (85.8) | 1046 (85.0) |
Females, n (%)† | 499 (76.4) | 441 (76.4) | 940 (76.4) |
Years from onset of symptoms, mean ± SD | 8.5 ± 7.7 | 8 · 5 ± 7.8 | 8.5 ± 7.8 |
Initial high-dose IFNβ, n (%) † | |||
IFNβ-1a | 467 (71.5) | 411 (71.2) | 878 (71.4) |
IFNβ-1b | 186 (28.5) | 166 (28.8) | 352 (28.6) |
Time on IFNβ in years, mean | |||
IFNβ-1a | 2.2 | 2.3 | 2.3 |
IFNβ-1b | 2.3 | 2.2 | 2.3 |
Initial antibody status, n (%) ‡ | |||
BAb (+) | 264 (40.4) | 231 (40.1) | 495 (40.3) |
Bab (+) NAb (+) | 118 (18.1) | 114 (19.8) | 232 (18.9) |
NAb titre in NAb (+) patients, n (%) | |||
Moderate | 39 (6.0) | 43 (7.5) | 82 (6.7) |
High | 79 (12.1) | 71 (12.3) | 150 (12.2) |